Outlook Therapeutics, Inc. OTLK
0.64
(0.02)
(3.03%)
as of 25 Sep
- Market cap
- $159.5M
- P/E
- 0.0×
Follow OTLK
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
118.61% | 231.56% | 198.37% | 256.92% | |
| (263.36%) | (583.69%) | (297.58%) | (251.66%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
219.61% | 322.56% | 339.04% | 1,109.13% | |
Average Days of Receivables |
69.32 | 6.90 | 2,980.27 | (515.83) | |
Free Cash Flow per Share |
(1.49) | (0.93) | (0.57) | (0.41) | |
Free Cash Flow |
(51.83) | (55.80) | (47.05) | (56.15) | |
Piotroski F-Score |
3.00 | 2.00 | 2.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(887.13%) | (822.07%) | (822.13%) | (294.37%) | |
Accounts Receivable Turnover |
3.15 | 18.29 | 0.24 | (0.69) | |
Accounts Payable Turnover |
0.15 | 0.14 | 0.14 | 0.13 | |
Inventory Turnover |
0.00 | 0.43 | 0.44 | 0.24 | |
Average Days of Payables |
2,698.36 | 1,912.02 | 3,241.97 | 2,233.61 | |
Days of Inventory on Hand |
883.82 | 903.45 | 795.10 | 1,654.87 | |
Tax Rate |
(0.02) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
346.22% | 349.14% | 6,378.99% | (1,492.46%) | |
Selling, General and Administrative Expense of Revenue |
508.72% | 604.10% | 11,445.12% | (3,093.68%) | |
Share Based Compensation of Revenue |
113.34% | 100.78% | 1,543.47% | (365.35%) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.83 | 0.54 | 0.77 | 0.92 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.23 | 0.10 | 0.00 | (0.01) | |
Operating CF per Share |
(1.49) | (0.93) | (0.57) | (0.41) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(795.14%) | (1,697.59%) | (18,299.76%) | 5,253.40% |
Columns are period end dates